苏沃雷生治疗酒精使用障碍与创伤后应激障碍:一项II期随机临床试验的研究方案
本研究为一项II期随机临床试验方案,拟纳入同时患有酒精使用障碍(AUD)与创伤后应激障碍(PTSD)且伴睡眠障碍、有内在戒烟动机的个体,采用酒精线索反应性人类实验室范式与尝试戒烟实验室模型,评估苏沃雷生(SUV)的安全性与早期疗效,并收集主客观睡眠指标以探讨其共同作用机制。
要点
- 苏沃雷生作为治疗AUD与PTSD共病的新型候选药物显示出明确前景。
- 研究结合酒精线索反应性与尝试戒烟实验室模型,进行成本/时间高效的早期疗效评估。
- 通过主客观睡眠测量评估苏沃雷生可能共同干预AUD与PTSD中间变量的机制。
核心结论
- 人类实验室建模与真实世界临床结局相结合,可提供独特且协同的数据集,以推进苏沃雷生的开发并识别其行为作用机制。
研究设计与样本
- II期随机临床试验方案,纳入同时患有AUD与PTSD、伴睡眠障碍且有内在戒烟动机的个体。
- 采用酒精线索反应性人类实验室范式与尝试戒烟实验室模型,评估苏沃雷生的安全性与初始疗效。
- 收集客观与主观睡眠测量指标,评估苏沃雷生共同干预AUD与PTSD中间变量的推定机制。
- 试验注册于ClinicalTrials.gov(NCT06679062),注册日期为2024年11月12日。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 原文未报告关键数值与推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alcohol use disorder (AUD) represents a highly prevalent, costly, and often untreated condition in the United States. Post-traumatic stress disorder (PTSD) represents a common comorbidity with AUD which worsens outcomes and decreases functional outcomes. Suvorexant (SUV) shows clear promise as a novel therapeutic candidate to treat AUD and PTSD. METHODS: This study features a promising compound (i.e., suvorexant), the application of a well-established human laboratory paradigm (i.e., alcohol cue reactivity), and a novel early efficacy laboratory model (i.e., practice quit attempt) to provide a cost/time-efficient evaluation of safety and initial efficacy of suvorexant for AUD with comorbid PTSD. Additionally, by collecting both objective and subjective sleep measures, the study provides an assessment of a putative mechanism through which suvorexant jointly addresses an intervening variable common to both AUD and PTSD. DISCUSSION: The combination of human laboratory modeling and real-world clinical outcomes provides a unique and synergistic set of data that can advance the development of suvorexant and identify its behavioral mechanisms of action. The recruitment of individuals with AUD and PTSD with sleep disturbances and who are intrinsically motivated to quit is a novel approach to screening pharmacotherapies by bridging the gap between experimental studies with non-treatment seekers and clinical trials with treatment-seeking individuals. TRIAL REGISTRATION: ClinicalTrials.gov NCT06679062 "Suvorexant for Treatment of AUD and PTSD (SUV)." Registered on November 12, 2024.
引用
- Ray LA, Nieto SJ, Miotto K, et al. Suvorexant for alcohol use disorder and post-traumatic stress disorder: study protocol for a phase II randomized clinical trial. Trials. 2026. PMID: 41630040. doi:10.1186/s13063-026-09489-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。